Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy with Concurrent Active TB or Other AIDS-Defining Disease
André Reynaldo Santos Périssé(Escola Nacional de Saúde Pública), Thomas Campbell(University of Colorado Anschutz Medical Campus), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Apsara Nair(Frontier Science & Technology Research Foundation, Inc.), James Hakim(University of Zimbabwe), Umesh Lalloo(Wentworth Hospital), Timothy Flanigan(Brown University), Ann Walawander(Frontier Science & Technology Research Foundation, Inc.), Laura Smeaton(Cancer Research And Biostatistics), Mulinda Nyirenda(University of Malawi), Yun Chen(Zhejiang Chinese Medical University), Cecilia Kanyama, Michael D. Hughes(Virginia Tech), Nagalingeswaran Kumarasamy(YR Gaitonde Centre for AIDS Research and Education), Breno Santos(Hospital Nossa Senhora da Conceição), Alberto La Rosa(Asociación Civil Impacta Salud y Educación)
Cited by 8
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
|New England Journal of Medicine|2011|541